Castle Biosciences (NASDAQ:CSTL) Stock: Insider Tobin Juvenal Sells 3,288 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 3,288 shares of the stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $32.67, for a total transaction of $107,418.96. Following the sale, the insider owned 35,565 shares of the company’s stock, valued at $1,161,908.55. This trade represents a 8.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Performance

Shares of NASDAQ CSTL traded down $0.71 during midday trading on Friday, reaching $33.79. 347,753 shares of the company were exchanged, compared to its average volume of 435,825. The company has a current ratio of 5.28, a quick ratio of 5.12 and a debt-to-equity ratio of 0.01. Castle Biosciences, Inc. has a 1 year low of $17.72 and a 1 year high of $44.28. The stock has a fifty day simple moving average of $34.35 and a 200 day simple moving average of $28.33. The stock has a market cap of $1.04 billion, a P/E ratio of -43.88 and a beta of 1.00.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.22. Castle Biosciences had a negative return on equity of 4.89% and a negative net margin of 6.10%. The firm had revenue of $101.95 million for the quarter, compared to analysts’ expectations of $92.76 million. On average, research analysts forecast that Castle Biosciences, Inc. will post -0.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on CSTL shares. Robert W. Baird boosted their target price on Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a report on Monday, November 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Castle Biosciences in a report on Thursday, October 29th. Wall Street Zen raised Castle Biosciences from a “hold” rating to a “buy” rating in a report on Sunday, November 1st. BTIG Research lifted their price objective on shares of Castle Biosciences from $44.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, November 9th. Finally, KeyCorp boosted their price objective on shares of Castle Biosciences from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Friday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Castle Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.50.

Institutional Investors Weigh In On Castle Biosciences

A number of hedge funds have recently added to or reduced their stakes in CSTL. Global Retirement Partners LLC purchased a new stake in Castle Biosciences in the 2nd quarter valued at approximately $26,000. Allworth Financial LP raised its stake in shares of Castle Biosciences by 255.3% during the 3rd quarter. Allworth Financial LP now owns 938 shares of the company’s stock worth $33,000 after buying an additional 674 shares in the last quarter. NFSG Corp purchased a new position in shares of Castle Biosciences during the 3rd quarter worth approximately $36,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Castle Biosciences during the 3rd quarter worth approximately $55,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Castle Biosciences in the 2nd quarter valued at approximately $62,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company’s portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett’s esophagus.